Can we predict who will develop a hypertrophic scar or keloid? An observational study on the association of cytokines with hypertrophic scarring and keloid.

Can we predict who will develop a hypertrophic scar or keloid? An observational study on the association of cytokines with hypertrophic scarring and keloid. - Cytokines and hypertrophic scarring

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31687

Enrollment

100

Registered

2008-05-26

Start date

2008-11-28

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abnormal scarring pathological scarring

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patient will undergo elective surgery by median sternotomy in the St. Antonius Hospital Nieuwegein - Patient is older than 18 years

Exclusion criteria

Exclusion criteria: - Incompetent - Connective tissue disease - Scarring of surgical site - Use of steroids - Participation in other trials

Design outcomes

Primary

Measure	Time frame
- Amount of TGF*-3 in the blood; - Patient and Observer Scar Assessment Scale scores; - Judgment of quality of wound healing by physician through photographs of the scar.	—

Secondary

Measure	Time frame
- Amount of TGF-1 in tissue specimens, blood and drainfluids; - Amount of TGF-2 in tissue specimens, blood and drainfluids; - Amount of TGF*-3 in tissue specimens, blood and drainfluids; - Amount of PDGF in tissue specimens, blood and drainfluids; - Amount of chemokines in tissue specimens, blood and drainfluids; - Amount of hydrocylysines (from which collagen I/III ratio is calculated) in tissue specimens; - Amount of pyridinoline cross-links per collagen molecule in tissue specimens; - Ratio collagenous-/non-collagenous proteins in tissue specimens; - Percentage of patients with HTS; - Percentage of patients with keloid; - Sociodemographic information; - Treatment related data; - Co-morbidity.	—

Measure

Time frame

- Amount of TGF*-1 in tissue specimens, blood and drainfluids; - Amount of TGF*-2 in tissue specimens, blood and drainfluids; - Amount of TGF*-3 in tissue specimens, blood and drainfluids; - Amount of PDGF in tissue specimens, blood and drainfluids; - Amount of chemokines in tissue specimens, blood and drainfluids; - Amount of hydrocylysines (from which collagen I/III ratio is calculated) in tissue specimens; - Amount of pyridinoline cross-links per collagen molecule in tissue specimens; - Ratio collagenous-/non-collagenous proteins in tissue specimens; - Percentage of patients with HTS; - Percentage of patients with keloid; - Sociodemographic information; - Treatment related data; - Co-morbidity.

—

Countries

Netherlands

Outcome results